Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
about
Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costsA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceEndogenous opiates and behavior: 2006Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression?Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians.Pharmacogenetics of OPRM1.Nerve growth factor β polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatmentMethadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activityOPRM1 gene variants modulate amphetamine-induced euphoria in humansABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.Role of cytochrome P4502B6 in methadone metabolism and clearance.Interindividual variability of methadone response: impact of genetic polymorphism.Variable response to opioid treatment: any genetic predictors within sight?Pharmacogenetics of analgesics: toward the individualization of prescription.Current evidence for a modulation of low back pain by human genetic variants.Personalized therapy in pain management: where do we stand?Pharmacogenetics of alcohol, nicotine and drug addiction treatments.A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.Pharmacogenomics of the human µ-opioid receptor.Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.µ-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain.Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.Pharmacogenomics of methadone maintenance treatment.Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships.β-Arrestin2 influences the response to methadone in opioid-dependent patients.Necessity and risks of arterial blood sampling in healthy volunteer studies.Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg.Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.Methadone Dosage and Plasma Levels, SNPs of OPRM1 Gene and Age of First Drug Use Were Associated With Outcomes of Methadone Maintenance Treatment
P2860
Q21284753-0C90B28C-AFB2-4573-B7DB-E46BF0237165Q27692040-9AE1411C-2F39-43FC-9419-B7FBFC7C4093Q28752585-3C8E6164-FBF9-41B2-A45E-1AE3FD298F03Q31104432-40D564DB-53B6-41ED-AB92-4D994F2DAD98Q33330500-E0715FF0-2366-4139-A680-2EADA1ABB832Q33568294-02A324CD-45A8-455E-8D37-423D3D7BD173Q35087543-5A73E03E-9AA9-4540-9C89-49B642527595Q35684822-53F2610E-F3FA-4949-A6EA-82B13447F79FQ36039431-FBF11E47-5CCC-4C2E-B8B4-5EE83D062214Q36441533-E0543986-1283-4DD5-8CB4-94A429B4903BQ36641884-97817BFB-FB22-4D74-9106-5057C6830B99Q37075089-AC06EE9D-EAA6-4302-AD0A-8A99EF1AB279Q37094439-AC1D6C86-C0CC-46A2-8E10-AB187208EA9CQ37142009-9EF6BBC8-7127-4219-AE76-12BD7631B291Q37187101-1FF1AD9A-0D40-4706-98A0-3BFE75F04D45Q37205954-E3D5DCAA-2C75-4D19-BA47-47D33A03D43EQ37396519-8FBD9206-9697-481D-8046-E79791B27AD7Q37760955-B6A75947-CDDB-40AB-9B7D-043F67B0C50EQ37848476-B9F972A9-BF1E-4C72-8745-7415B5F804D6Q37895002-2BEA42F3-E3FF-4C66-8677-EB17F0E5149AQ37932516-E0EA8D76-721F-4EC3-8FD2-5F70D62C9986Q38093852-1E045AE1-48F8-45CB-9A19-E1D44A7C6B8FQ38162871-9BE1AAEB-76D4-4679-A4DE-395CCBF81D38Q38184547-530402FA-54F3-4E5A-AA76-21575CE38560Q38222510-28D5B45B-A32E-4537-96CB-326EBF763896Q38243832-A86254E7-8B2A-478D-80B9-04595B69FF76Q38478413-D2FD4539-2985-41C9-9B4A-11B3CFAC433FQ42861755-2894CC5C-4B27-4144-9A29-8997BD92958AQ44346717-54682099-411C-4974-BC17-28FB0EB7C788Q48127644-4A98A226-10B7-4C0C-9662-CB86E0F05F62Q48490118-02A375CE-4D9B-4653-B51B-FEB7E7C82E24Q54562217-5D5E7927-2539-425C-AD1A-0DA33D223B97Q58694808-D1CDE343-D1ED-497E-A338-6B2A858991D6
P2860
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Modulation of the central nerv ...... distribution, and drug action.
@en
Modulation of the central nerv ...... distribution, and drug action.
@nl
type
label
Modulation of the central nerv ...... distribution, and drug action.
@en
Modulation of the central nerv ...... distribution, and drug action.
@nl
prefLabel
Modulation of the central nerv ...... distribution, and drug action.
@en
Modulation of the central nerv ...... distribution, and drug action.
@nl
P2093
P1476
Modulation of the central nerv ...... distribution, and drug action.
@en
P2093
Bruno Georg Oertel
Gerd Geisslinger
Helmut Schmidt
Johannes Wieting
Jürgen Brockmöller
P356
10.1016/J.CLPT.2005.09.010
P407
P577
2006-01-01T00:00:00Z